CytoMed Therapeutics (CytoMed Therapeutics) Margin of Safety % (DCF FCF Based) : N/A (As of May. 28, 2024)

View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

CytoMed Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of CytoMed Therapeutics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, CytoMed Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoMed Therapeutics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's Margin of Safety % (DCF FCF Based) falls into.

CytoMed Therapeutics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

F98:Germany

Address

1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544

Website

https://w2.cytomed.sg

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

Executives

Chee Kong Choo	director, 10 percent owner	COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng	director, officer: CSO and CMO	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang	10 percent owner	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan	director, officer: Chief Operating Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd	10 percent owner	18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee	director, officer: Chief Clinical Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh	director	1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544